Global Patient-centric Healthcare App Market - Growth, Trends, COVID-19 Impact, and Forecast (2022 - 2027)

出版日期: | 出版商: Mordor Intelligence Pvt Ltd | 英文 110 Pages | 商品交期: 2-3個工作天內



  • 全貌
  • 簡介
  • 目錄








  • 市場概況
  • 市場驅動力
    • 心臟病和中風相關死亡的全球患病率
    • 通過新技術改善訪問和靈活性
  • 市場限制因素
    • 高昂的開發成本
    • 常規醫護人員的抵抗
  • 波特的五力分析


  • 按操作模式
    • 基於電話
    • 基於Web
    • 以患者為中心的APP
  • 按應用
    • 健康管理
    • 疾病和治療的管理
    • 其他
  • 按地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東/非洲
    • 南美洲


  • 公司簡介
    • F. Hoffmann-La Roche Ltd
    • iPatientCare Pvt Ltd
    • Merck & Co Inc
    • MobileSmith Inc
    • Koninklijke Philips NV
    • Pfizer Inc
    • Siemens Healthineers AG
    • Novartis AG
    • Bayer AG
    • Hill-Rom Holdings Inc


Product Code: 68524

The patient-centric healthcare app (PCHA) market is anticipated to register a CAGR of nearly 20.5% during the forecast period.

The COVID-19 pandemic had an impact on the healthcare industry. The outbreak of COVID-19 led to disruption, challenges, limitations, and changes in each sector of every industry. The studied market was also impacted by the pandemic. The outbreak of COVID-19 showed a positive impact on the market, as lockdowns led to the lower availability of doctors in clinical settings.

Thus, patients were more inclined to use apps to manage their chronic conditions, such as diabetes, hypertension, and other chronic diseases. Moreover, there have been a large number of patient care apps, which were launched for COVID-19 management. Nationwide lockdowns resulted in providing healthcare services by the hospitals and clinics, which led to the rise in the use of patient-centric healthcare app that aims toward the management of diseases.

For instance, according to a research study by Haridimos Kondylakis et al., published in the Journal of Medical Internet Research December 2020, mobile apps were considered to be a valuable tool for health professionals, citizens, and decision-makers in facing critical challenges imposed by the pandemic such as reducing the burden on hospitals, tracking the symptoms and mental health of individuals, providing access to credible information, and discovering new predictors, leading to the high adoption of mobile health apps across the industry both from providers and consumers.

The major factors driving the market growth include the increased incidence of chronic disorders, such as cancers, diabetes, and rheumatoid arthritis, especially in the geriatric population. The treatment for chronic diseases requires continuous monitoring and evaluation of physiological changes for proper diagnosis and medication.

For instance, according to the research article by M. Kloppenburg et al., published in Osteoarthritis and Cartilage Journal 2020, globally, osteoarthritis is a highly prevalent rheumatic musculoskeletal disorder that affected around 303 million people in 2017. It can affect any joint but preferentially affects the hands, knee, hip, and spine. Osteoarthritis has a considerable impact on the individual patient, resulting in pain and disability, and on society which is expected to boost the market in the near future.​

According to the United Nations World Population Prospects 2019 report, people over 65 years of age increase from 9% in 2019 to more than 16% of the total world's population by 2050. Thus, the growing elderly population, rise in government initiatives to maintain electronic health record systems, and increased demand for technology-based treatment to avoid medication errors are likely to drive the patient-centric healthcare app (PCHA) market over the forecast period.

Key Market Trends

The Phone-based Apps Sub-segment is Expected to Hold Significant Market Share in the Patient-centric Healthcare App Market

The phone-based apps are expected to account for the largest revenue share in the overall patient-centric healthcare app market over the forecast period.

During the COVID-19 pandemic 2020, the maintenance of healthcare, well-being, and social connection was crucial for the elderly population. Many mobile health apps were launched after countries relaxed their telehealth regulations to combat the COVID-19 pandemic. Mobile health apps helped patients regarding their health condition and physicians in delivering the services on their premises.

For instance, in January 2021, in India, Dell Technologies, in collaboration with the Ministry of Health and Family Welfare and Tata Trusts, developed a mobile application to manage non-communicable diseases at the government primary health centers (PHCs) across the country.

The major factors driving the segment growth include a rise in healthcare awareness, enhanced interoperability, remote access to data, and a relatively reduced time of treatment. The reduced IT burden in hospitals and huge investments in the phone-based apps specific to treatment by market players, such as Pfizer Inc. and Novartis AG, are likely to drive the segment over the forecast period.

According to the International Diabetes Federation (IDF) facts and figures, approximately 463 million adults (20-79 years) had diabetes in 2019. This number is expected to increase to 700 million by 2045. The proportion of people with type 2 diabetes is increasing in most countries. Moreover, 79% of adults with diabetes were in low- and middle-income countries.

The market players adopting various strategies, such as product launches, collaborations, mergers, and acquisitions, to increase their market shares. For instance, in April 2018, Novartis AG launched FocalView app, a first-of-its-kind app designed to modernize ophthalmic clinical trials. The phone-based app provides an opportunity for patients to participate in ophthalmology clinical trials from home, allowing more sensitive trial endpoints and accurate patient-reported outcomes with enhanced access and flexibility. Thus, the above-mentioned factors are expected to drive market growth over the forecast period.

North America Dominates the Market and Expected to do the Same in the Forecast Period.

North America is expected to dominate the overall patient-centric healthcare app (PCHA) market throughout the forecast period. The dominance is due to a huge target population base with chronic diseases, such as coronary heart diseases, atrial fibrillation, stroke, hypertension, and diabetes, in the region.

As per the American College of Cardiology Foundation 2021, deaths from hypertensive diseases and ischemic heart disease in the United States increased during the COVID-19 pandemic in 2020, leading to the increasing use of patient-centric health care app during the pandemic in the United States in the management of the disease.

The rising geriatric population and the high burden of chronic diseases in the country are expected to boost the market growth. For instance, according to the American Heart Association, in 2018, nearly 92.1 million individuals in the United States suffered from cardiovascular diseases, which resulted in higher demand for better treatment technologies driving the market.

The rising prevalence of chronic disease and increased healthcare costs in the United States encourage stakeholders to develop new solutions to tackle issues. Moreover, digital health innovations like mobile health applications facilitate care prevention and management for chronic disease, but significant gaps remain in their ability to be used in real-world practice.

According to the American Diabetes Federation 2019 report, an estimated 463 million adults live with diabetes worldwide, and the number is estimated to reach 700 million by 2045.

Furthermore, a rise in healthcare expenditure, health awareness, and a shift from clinical-centric treatment to patient-centric care boosts the market in the region. The growing adoption of technology by key healthcare providers in the region is expected to contribute to the significant share of the global market throughout the forecast period.

Competitive Landscape

The patient-centric healthcare app market is moderately competitive. Some of the companies are expanding their market position while others are adopting various strategies, such as mergers and acquisitions, introducing new products, and upgrading the technologies, to maintain their market position. Some of the market players are Koninklijke Philips N V, Merck & Co. Inc., Hill-Rom Holdings Inc., Bayer AG, and Siemens Healthineers AG.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support



  • 1.1 Study Assumptions
  • 1.2 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Chronic Diseases and Rising Geriatric Population
    • 4.2.2 Enhanced Access and Flexibility with Novel Technologies
  • 4.3 Market Restraints
    • 4.3.1 The High Cost of Development
    • 4.3.2 Reluctance by Regular Healthcare Providers
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Mode of Operation
    • 5.1.1 Phone-based
    • 5.1.2 Web-based
    • 5.1.3 Hybrid Patient-centric Apps
  • 5.2 By Application
    • 5.2.1 Wellness Management
    • 5.2.2 Disease And Treatment Management
    • 5.2.3 Other Applications
  • 5.3 Geography
    • 5.3.1 North America
      • United States
      • Canada
      • Mexico
    • 5.3.2 Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.3.3 Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • GCC
      • South Africa
      • Rest of Middle-East and Africa
    • 5.3.5 South America
      • Brazil
      • Argentina
      • Rest of South America


  • 6.1 Company Profiles
    • 6.1.1 Boston Scientific Corporation
    • 6.1.2 iPatientCare Pvt Ltd
    • 6.1.3 Merck & Co. Inc.
    • 6.1.4 MobileSmith Inc.
    • 6.1.5 Koninklijke Philips NV
    • 6.1.6 Pfizer Inc
    • 6.1.7 Siemens Healthineers AG
    • 6.1.8 Novartis AG
    • 6.1.9 Bayer AG
    • 6.1.10 Hill-Rom Holdings Inc.
    • 6.1.11 athenahealth Inc.
    • 6.1.12 Allscripts Healthcare Solutions Inc.
    • 6.1.13 International Business Machines Corporation (IBM)
    • 6.1.14 Klick Inc.
    • 6.1.15 Cerner Corporation